In recent years, nitrosamine impurities have drawn intense global regulatory attention due to their potential toxic risks. Regulators including the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (US FDA) have continuously tightened oversight over nitrosamine-related risks, covering active pharmaceutical ingredient (API) manufacturing processes, excipients and primary packaging materials. Such oversight aims to fully identify nitrosamine impurities and their precursor sources, ensuring drug products stay free of safety hazards throughout their shelf life.

Backed by a leading technical platform and a team of seasoned scientists, Milestone Pharma has built a full-spectrum, compliant and efficient research platform for nitrosamine impurities. We provide robust technical support for pharmaceutical enterprises to resolve technical hurdles and advance global product development.

01 Industry Challenges in Nitrosamine Impurity Research

EMA and US FDA regulators have ramped up scrutiny of nitrosamine origins spanning APIs, process impurities, excipients and primary packaging materials. These sources may directly introduce nitrosamine impurities or their precursors, which can further react during product storage to generate nitrosamine contaminants.

Four prevalent challenges exist in nitrosamine impurity research:

  • Impurity profiles must be assessed on a case-by-case basis, with no universal solution applicable to all products.

  • Analytical methods need to reach ultra-low detection and quantitation limits at the ng/pg level while overcoming severe interference from complex sample matrices.

  • Matrix components can trigger false positive signals, requiring highly specific analytical workflows.

  • Sourcing or synthesizing reference standards for certain Nitrosamine Drug Substance-Related Impurities (NDSRIs) poses an industry-wide difficulty.

Key Industry Challenges

  1. Product-Specific Impurity Profiles Impurity characteristics differ across products and require individualized evaluation.

  2. Ultra-Low Quantitation Limits Ultra-trace quantification must be achieved within complex sample matrices.

  3. Risk of False Positive Results High method specificity is mandatory to avoid analytical misjudgments.

  4. Limited Access to Reference Standards Certain NDSRI reference standards are hard to source or synthesize.

02 Nitrosamine Impurity Research Services

Supported by a world-class technical platform and a panel of senior specialists, Milestone Pharma delivers full-suite, compliant and efficient integrated nitrosamine impurity research services to help clients successfully launch products onto global markets.

Integrated Nitrosamine Impurity Research Service Lines

  1. Risk Assessment Full-spectrum risk identification based on API synthetic routes, excipients and primary packaging materials.

  2. Analytical Method Development, Validation & Verification Customized product-specific analytical methods with complete validation or verification.

  3. Batch Release Testing & Confirmatory Testing Guarantee every production batch meets official quality specifications.

  4. Investigation of False Positive Results Accurate discrimination and root-cause analysis to avoid misinterpretation of test data.

  5. ppb-Level Trace Nitrite Testing for Raw Materials & Excipients Mitigate potential risks at the source of production.

  6. Risk Assessment Screening Methods Rapid preliminary screening to evaluate product-specific nitrosamine risks.

  7. Custom Synthesis of NDSRI Reference Standards Address the industry bottleneck of insufficient NDSRI reference standard supply.

  8. Comprehensive Structural Elucidation of NDSRI Reference Standards Guarantee the accuracy and credibility of analytical test results.

  9. Forced Degradation Studies for NDSRIs Deepen understanding of impurity formation pathways and support formal stability testing.

03 Customized Solutions

With extensive experience analyzing and testing nitrosamine impurities in diverse drug formulations, APIs and raw materials, paired with in-depth expertise in nitrosamine chemical properties, Milestone Pharma delivers tailor-made solutions aligned with the latest scientific guidelines and regulatory requirements to resolve clients’ unique technical pain points.

Sample Pretreatment Optimization

We optimize sample pretreatment workflows for simple low-molecular-weight nitrosamines such as NDMA and NDEA, as well as structurally complex NDSRIs. Our analytical methods are refined to achieve limits of quantitation (LOQs) no higher than 10% of the regulatory acceptable intake (AI).

Advanced Analytical Instruments & Expert Team

Our laboratories are equipped with cutting-edge analytical equipment including LC-MS/MS, GC-MS/MS and high-resolution mass spectrometry (HRMS). Operated by senior analytical scientists, these systems support impurity quantification at pg/mL to ng/mL trace levels.

Trace Nitrite Testing for Excipients & Raw Materials

We offer rapid screening for trace nitrite residues in excipients and manufacturing raw materials, enabling timely tracing of potential nitrosamine risk sources and supporting appropriate excipient selection.

04 Core Strengths of Milestone Pharma

Milestone Pharma has long specialized in nitrosamine impurity research with proven track records, cementing our leading position in this technical field.

  • Professional team of over 30 specialists, more than 40% holding master’s or doctoral degrees

  • Over 200 formulation research projects completed with full nitrosamine risk assessment

  • More than 1,000 nitrosamine analytical methods independently developed and fully validated

Six Core Competitive Advantages

  1. Extensive In-House Reference Standard Library A collection of over 500 NDSRI reference standards, supported by full structural elucidation and quantitative testing services.

  2. Fast Project Delivery Turnaround Our proprietary expedited Mingshift Service can complete method development, validation and final reporting within four weeks upon sample receipt for standard small-molecule APIs.

  3. Dedicated Independent Testing Laboratories Separate testing rooms exclusively for nitrosamine and genotoxic azide impurity analysis to eliminate cross-contamination risks.

  4. Source-Oriented Full Lifecycle Risk Assessment Root-cause risk evaluation reports built around full synthetic pathways to target core safety hazards.

  5. Effective Mitigation of False Positive Interference Rich practical experience and high-end instrumentation help reduce matrix-induced false positive signals.

  6. Full cGMP Compliance Guarantee All testing activities are carried out in cGMP-compliant laboratories audited and recognized by multiple global regulatory authorities.

From impurity risk evaluation and custom reference standard synthesis to rapid trace testing and full regulatory compliance support, Milestone Pharma provides pharmaceutical manufacturers with professional technical backing to facilitate global product commercialization.

Moving forward, Milestone Pharma will keep expanding our capabilities in pharmaceutical quality research and continuously upgrade our technical workflows and service systems. If you have any demands related to nitrosamine impurity research or pharmaceutical quality control, please feel free to contact us. We stand ready to collaborate with you to drive high-quality development across the pharmaceutical sector and jointly safeguard global drug safety.